What's Happening?
A recent international clinical trial, known as the PISCES trial, has revealed that daily intake of omega-3 fish oil supplements can significantly lower the risk of major cardiovascular events in patients undergoing dialysis for kidney failure. The study,
conducted across 26 sites in Australia and Canada, involved 1,228 participants and was presented at the American Society of Nephrology Kidney Week 2025. Participants who consumed four grams of fish oil daily experienced a 43% reduction in serious cardiovascular events, such as heart attacks, strokes, and cardiac deaths, compared to those who received a placebo. The trial was led by Monash Health and the School of Clinical Sciences at Monash University, with significant contributions from Professor Kevan Polkinghorne.
Why It's Important?
The findings of the PISCES trial are particularly significant for dialysis patients, who are at an extremely high risk of cardiovascular complications. This study provides a potential therapeutic option to mitigate such risks, which have been challenging to address with existing treatments. The reduction in cardiovascular events could lead to improved quality of life and reduced healthcare costs for this vulnerable population. The trial's results are specific to hemodialysis patients, highlighting the need for targeted interventions in this group. The study also underscores the importance of omega-3 fatty acids, EPA and DHA, which are often deficient in dialysis patients.
What's Next?
Following the promising results of the PISCES trial, further research may be conducted to explore the broader applicability of omega-3 supplements in other patient groups. Healthcare providers might consider incorporating fish oil supplements into the standard care regimen for dialysis patients. Additionally, the findings could prompt discussions among nephrologists and healthcare policymakers about revising treatment guidelines to include omega-3 supplementation as a preventive measure against cardiovascular events in dialysis patients.
